Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis

Maria Rosaria Valerio1, Pietro Spadaro2, Concetta Arcanà2, Nicolo Borsellino3, Calogero Cipolla4, Paolo Vigneri5, Dario Piazza6 & Vittorio Gebbia*,6,7,8

1Medical Oncology Unit, Policlinico Paolo Giaccone, University of Palermo, Italy
2Medical Oncology Unit, Casa di Cura Villa Salus, Messina, Italy
3Medical Oncology Unit, Hospital Buccheri La Feria, Palermo, Italy
4Surgical Oncology Unit, Policlinico Paolo Giaccone, Palermo, Italy
5Medical Oncology Unit, Policlinico, Catania, Italy
6GSTU Foundation for the Study of Tumors, Palermo, Italy
7Department Promise, University of Palermo, Palermo, Italy
8Medical Oncology Unit, La Maddalena Clinic for Cancer, Palermo, Italy
*Author for correspondence: vittorio.gebbia@gmail.com

A retrospective analysis of 70 patients with triple-negative or hormone-resistant advanced breast carcinoma who had not previously received chemotherapy was carried out. Patients received oral vinorelbine 60 mg/m² on day 1 and 8, plus capecitabine 1000 mg/m² bid for 14 consecutive days every 3 weeks. Overall response rate was 53% with a 9% complete response rate. Stable disease was recorded in 27% of the cases. Median progression-free survival was 7.9 months and median overall survival was 29.2 months. Toxicity was generally mild and easily manageable. These data demonstrate that this combination is feasible, safe and active as first-line treatment of triple-negative fully hormone-resistant advanced breast carcinoma patients.

Lay abstract: The adoption of metronomic chemotherapy in the treatment of breast cancer is an important step forward in the management of this disease. The fluoropyrimidine capecitabine and the vinca alkaloid vinorelbine have been shown to be at least as active. Our data confirm the activity and safety of this all-oral regimen as first-line metronomic therapy being response rate.

First draft submitted: 29 May 2020; Accepted for publication: 16 September 2021; Published online: 12 November 2021

Keywords: breast carcinoma • capecitabine • metastases • oral chemotherapy • vinorelbine

Intravenous administration of chemotherapy (CT) represents a significant physical, emotional and social burden for both patients and health providers in terms of complications and economic costs associated with the implant and management of indwelling venous access catheters and pumps as well as the growing numbers of hospital accesses for intravenous (iv.) therapy [1]. Several studies have clearly shown that patients themselves generally prefer oral CT if equal efficacy to iv. therapy is assured [1]. Therefore, all oral CT represents a very reasonable therapeutic option in consideration of the palliative nature of the treatment of metastatic breast cancer (MBC). The adoption of metronomic chemotherapy in the treatment of breast cancer is an important step forward in the management of this disease. Thus, the continuous administration of low-dose drugs allows to increase the time of treatment, minimizing the risk of side effects. Clinical experience and data from several studies suggest that this approach should be offered at the present time primarily to patients with HR positive, while waiting for data from ongoing studies on triple-negative and HER2-positive disease [2].

The fluoropyrimidine capecitabine (CAP) and the vinca alkaloid vinorelbine (VNR) have been shown to be at least as active as iv. counterparts. The two drugs have been compared in an European Organisation for Research and Treatment of Cancer (EORTC) prospective Phase II trials in patients pretreated with taxanes and anthacyclines showing equi-activity but a different toxicity profile, being hand foot syndrome and diarrhea more frequent with
CAP and neutropenia more incident for VNR [3]. Dose-finding studies of oral VNR plus CAP have consistently shown that the combination is feasible and well tolerated. Severe neutropenia was the dose-limiting toxicity and the recommended doses of VNR and CAP were respectively 80 mg/m² day 1 and 8 and 1000–1200 mg/m² bid day 1→14 every 3 weeks [4].

This all oral regimen has been tested with good results [5], but in this paper we report our experience in a challenging setting such as first-line treatment of triple-negative or fully hormone-resistant HER-negative MBC.

Materials & methods
Study design
Patients with triple-negative or hormone-refractory MBC treated with oral VNR/CAP as first-line treatment were anonymously collected and retrospectively analyzed for clinical efficacy and toxicity after communication to the ethical committees from January 2008 up to December 2014. Patients lacking clinical and/or radiological evidence of response and/or certain data for time-related parameters were excluded from final analysis. Clinical data for all patients were submitted for external review.

Eligibility criteria
Eligible patients included in this retrospective analysis had to meet the following entry criteria: age ≥18 years, performance status ≤ according to the ECOG scale, pathologically confirmed diagnosis of MBC, no previous treatment with chemotherapy for advanced and/or metastatic disease while previous adjuvant chemotherapy with anthracyclines and/or taxanes were allowed. Patients with positive estrogen receptors could have received multiple lines of hormonotherapy. Blood cell counts had to be permissive for chemotherapy (white blood cells [WBCs] > 3500/mm³; platelet [PLT] > 100,000/mm³). Renal (blood urea nitrogen [BUN] < 50 mg %; serum creatinine < 1.2 mg %) and liver (serum bilirubin < 1.2 mg %; serum transaminases within two-times the normal values) functions had to be within the normal limits. Metastatic disease had to be also measurable disease according to the RECIST criteria [4] with the absence of clinically detectable deposits in the CNS. Patients were excluded if osteoblastic bone lesion or ascites were the only sites of disease. No history of previous malignancies other than basal cell skin cancer or curatively treated carcinoma in situ of the cervix was allowed as well as severe and uncontrolled metabolic, infectious, cardiological or neurological disease.

Chemotherapy schedules
Patients received oral VNR 60 mg/m² on day 1 and 8 with water 30 min after a meal plus CAP 1000 mg/m² twice daily for 14 consecutive days followed by 1-week rest. Oral anti-HT3 drugs were employed before VNR administration, while no prophylaxis for emesis was employed for CAP administration. In case of nausea and/or vomiting related to CAP patients were treated with oral metoclopramide. Both patients and caregivers were informed to report any side effect weekly, according to our institution procedures for oral antineoplastic treatments. Data of hematological toxicity or other serum chemistry test were inferred from analysis routinely done before every CT administration.

Patients evaluation
Patients were staged for disease extension and response evaluation with physical examination, chest x-rays, chest and abdominal CT scan, sonograms, bone scans, complete blood counts and serum chemistry tests as needed. Objective responses were recorded according to the RECIST criteria and results were reported as best overall response [6]. The sum of complete and partial responses (CR and PR) was defined as the overall response rate (ORR). The sum of ORR and stabilization of disease (SD) was defined as the tumor growth control rate (TGCR).

Safety evaluation
Evaluation of tolerance and side effects was carried out according to National Cancer Institute Common Toxicity Criteria (NCI CTC) version 2.0 criteria by clinical and laboratory investigations. Dose modifications were performed in a very flexible way depending on the type, severity and duration of side effects. Patients and caregivers were required to report toxicity employing a dedicated fax or telephone line. Complete blood counts were obtained before any oral VNR administration. CAP was stopped in case of grade 3–4 skin of gastrointestinal toxicity and subsequently administered with a 25–50% dosage reduction. Oral VNR was reduced by 25% if grade-4 hema-
Table 1. Patient baseline characteristics.

| Patients clinical and demographic characteristics | Patients (n) | Percent |
|---------------------------------------------------|-------------|---------|
| Enrolled patients                                  | 70          | 100     |
| Median age, years (range)                          | 63 (46–76)  |         |
| Performance status:                                |             |         |
| ECOG 0                                             | 48          | 69      |
| ECOG 1                                             | 14          | 21      |
| ECOG 2                                             | 8           | 12%     |
| Histology:                                         |             |         |
| Ductal infiltrating carcinoma                      | 66          | 94      |
| Lobular carcinoma                                  | 4           | 6       |
| Hormone receptors:                                 |             |         |
| Positive                                           | 40          | 57      |
| Triple negative                                    | 30          | 43      |
| HER status negative†                               | 70          | 100     |
| Previous treatments:                              |             |         |
| Surgery                                            | 68          | 97      |
| Radiotherapy                                       | 61          | 87      |
| Adjuvant hormonal therapy                          | 40          | 57      |
| Adjuvant chemotherapy                              | 61          | 87      |
| Hormonal therapy (advanced disease)                | 40          | 57      |
| Aromatase inhibitors                              | 39          | 56      |
| Tamoxifen                                          | 1           | 1       |
| Faslodex                                           | 40          | 57      |
| Everolimus - exemestane                            | 18          | 26      |
| Type of chemotherapy:                              |             |         |
| Anthracyclines                                     | 18          | 26      |
| Taxanes                                            | 43          | 61      |
| CMF                                                | 6           | 9       |
| Sites of disease:                                  |             |         |
| Bone                                               | 41          | 59      |
| Lung                                               | 16          | 23      |
| Liver                                              | 21          | 30      |
| Nodes                                              | 24          | 34      |
| Skin                                               | 5           | 7       |
| Metastatic sites (n):                              |             |         |
| 1                                                  | 15          | 21      |
| 2                                                  | 30          | 43      |
| ≥3                                                 | 25          | 36      |

† Other than HER 3+
CMF: Cyclophosphamide, methotrexate, 5-fluorouracil; ECOG: Eastern Cooperative Oncology Group.

Institutional toxicity. Granulocyte colony-stimulating factor (G-CSF) was employed according to clinical needs and physician's decision.

Statistical methods
Response duration was calculated from the start of CT until the date when progression was evidenced, or last follow-up evaluation or death. Progression-free survival (PFS) was calculated from the date of first CT cycle until progression. Overall survival (OS) was calculated from the first day of CT to the time of death or last follow-up evaluation. Objective response was evaluated as relative rates with their 95% confidence limits (95% CL). A univariate analysis of survival data according to product-limit estimate (Kaplan–Meier) was performed employing the computer statistical software Prism (Graph Pad Incorporated, CA, USA). Calculation of dose intensity was carried out according to Hryniuk [7].

Results
Patient population
Between January 2008 and December 2014, 94 patients were treated in four centers. However, 70 patients (80%) were considered evaluable and 24 were excluded from the analysis because of incomplete objective response and survival data.

Baseline characteristics of the 70 evaluable patients are shown in Table 1. All patients had recurrent disease after more than 12 months after the completion of an adjuvant therapy. Thirty-seven patients (54%) had dominant
visceral metastatic disease and 33 (47%) patients had extra-visceral dominant disease. Thirty patients (43%) had triple-negative metastatic disease. Forty patients (57%) with hormone-refractory MBC had previously received first-line hormonotherapy with an aromatase inhibitor but one patient who received tamoxifen, and a second-line treatment with high-dose fulvestrant. Among these patients with hormone-positive MBC 18 cases (26%) received a third-line hormonotherapy with everolimus plus exemestane. Lack of response to hormonal manipulations accordingly to treating physician decision classified patients as hormone-refractory.

**Clinical efficacy**

Six out of 70 patients fully evaluable for response efficacy achieved a CR (9%; 95% CL: 0–31.0), 31 patients showed a PR (44%; 95% CL: 30.9–57.1), for an ORR of 53% (95% CL: 41.9–64.1) (Table 2). Nineteen patients were categorized as SD (27%; 95% CL: 9.9–44.1) and 14 patients as PD (20%; 95% CL: 1.2–38.8). TGCR was 80% (95% CL: 75.3–84.7). Deepness of response is shown in Figure 1. Median PFS was 7.9 months (range: 2–15 months) and median OS was 29.2 months (range: 13–41 months). No statistically significant relationship was found between site or number of metastases and objective response, or between triple-negative and hormone-resistant patients. ORR was 50% in the group of TNBC and 55% in the hormone-refractory one.

**Safety**

Side effects are depicted in Table 3. Globally 411 cycles were administered with a median of 5.9 cycle/patient (range: 3–12). No chemotherapy-related deaths as well as treatment discontinuations due to toxicity were observed. Of the 70 patients analyzed, 19% withdrew from treatment after the third cycle because of the occurrence of

---

**Table 2. Treatment outcomes.**

| Objective response (RECIST criteria) | Patients (n) | Percent | 95% CL |
|--------------------------------------|-------------|---------|--------|
| Evaluable patients                   | 70          | 100%    |        |
| Overall response                     | 37          | 53%     | 41.9–64.1 |
| Complete response                    | 6           | 9%      | 0–31.0 |
| Partial response                     | 31          | 44%     | 30.9–57.1 |
| Stable disease                       | 19          | 27%     | 9.9–44.1 |
| Tumor growth control                | 56          | 80%     | 75.3–84.7 |
| Progressive disease                  | 14          | 20%     | 1.2–38.8 |

**Survival parameters**

| Median | Range |
|--------|-------|
| 7.9 months | 2–15 months |
| 29.2 months | 13–41 months |

CL: Confidence limits.

---

![Figure 1. Tumor shrinkage.](image-url)
progressive disease. Grade 3 and 4 leukopenia and neutropenia were recorded in 21 and 16% of cases respectively, but G-CSF administration was required only in four cases. Overall, toxicity-related dose reductions were made in 16 patients mainly due to white blood cell and/or platelet toxicity or hand-foot syndrome (HFS). Median duration of interval among courses was 22.6 days. The planned dose-intensity was 40 mg/m²/week for oral VNR and 9333 mg/m²/week for CAP. The received, relative median dose-intensity of oral VNR and CAP were 0.94 (37.6 mg/m²/week) and 0.89 (8306 mg/m²/week), respectively. Statistical analysis performed in the attempt to correlate response rate with dose-intensity was not significant.

### Discussion

In this article we report our experience with an all-oral regimen of VNR 60 mg/m² on days 1 and 8 plus CAP 1000 mg/m² bid for 14 consecutive days every 3 weeks in a series of 70 patients with triple-negative or hormone-resistant HER-2 negative MBC previously untreated with CT for advanced disease. In our hands, this all-oral combination resulted active and very well tolerated. As shown in Table 2, overall a CR was recorded in 9% of patients, PR in 44% and SD in 27% of cases, for a TGCR of 80%. Median PFS and overall survival were 7.9 and 29.2 months respectively. This multicentric study, albeit retrospective, demonstrates the activity of this combination in a challenging clinical setting such as triple-negative MBC patients and in hormone-resistant patients progressing after several lines of hormonal manipulations. This report is interesting since data in triple-negative patients with such all-oral chemotherapy are scarce in medical literature although there is a recent scientific leap oriented to fill this gap, especially in the perspective of precision medicine [8–10]. Moreover published trials often include very low numbers of triple-negative patients with the exception of the paper of Campone et al. [11].

Overall, our data confirm the activity and safety of this all-oral regimen as first-line metronomic therapy being response rate, survival parameters and toxicity in the range reported in medical literature by other authors [11–19]. Table 4 shows the main studies reporting the activity and toxicity of this all-oral combination of VNR and CAP. All studies, but one, consistently reported an ORR ≥51% (range: 51–76%). Only the study by Gampenrieder et al. reported a somewhat lower ORR of 36.7% but authors employed a dose of CAP of only 500 mg/m² bid which may explain the lower activity [15]. However other authors have shown that ORR with oral VNR + CAP is not statistically different between patients who received more or less than the median dose intensity, with no difference in OS or PFS. The use of lower doses than those currently recommended – if clinically advisable – should be not detrimental in terms of efficacy. In 2016 Cazzaniga et al. reported an open label Phase II study on the all-oral combination of VNR and CAP on a true metronomic schedule reporting a quite low rate of grade 3–4 toxicity per cycle, being non febrile neutropenia and hand-foot syndrome the most frequently reported side effects. Out of 35 patients treated in first-line only 13 had TNBC and their outcome in terms of time-to-progression was very similar to those with hormone sensitive disease. The status of hormone refractoriness and the number of previous lines was of hormonal manipulation were unclear. However, these results are superimposable to those achieved in the present experience.

As shown in Table 3 both pattern and severity of side effects reported in our experience fit in the range reported by other authors. Hematological and gastrointestinal toxicity were the most common side effects and, in most cases,
Table 4. Studies reporting the activity and toxicity of first-line all-oral combination of vinca alkaloid vinorelbine and capecitabine.

| Study (year)         | Patients (n) | Adjuvant chemotherapy | Schedule                          | ORR  | Median PFS (months) | Median OS (months) | Grade 3–4 toxicity (> 10%) | Ref. |
|----------------------|--------------|-----------------------|-----------------------------------|------|--------------------|--------------------|---------------------------|------|
| Nolé et al. (2009)   | 42           | 78.8% anthracyclines 60.5% Taxanes 5.8% | VNR 60 mg/m² Day 1 + 8 q21 days CAP 1 gr/m² bid Day 1 – 14 | 54.8% | 8.4                | 25.8               | Neutropenia G3 21%; G4 25% | [13] |
| Tubiana-mattieu et al. (2009) | 49           | 63% anthracyclines 37.1% Taxanes 5.8% | VNR 60–80 mg/m² Day 1 + 8 q21 days CAP 1 gr/m² bid Day 1 – 14 750 mg/m² >65 years | 51.0% | 8.4                | 29.2               | Neutropenia G3 26%; G4 23% | [14] |
| Finek et al. (2009)  | 58           | Anthracyclines (mostly) | VNR 60 mg/m² Day 1 + 8 q21 days CAP 1 gr/m² bid Day 1 – 14 | 56.5% | 10.5               | 17.5               | -                         | [12] |
| Gampenrieder et al. (2010) | 24           | 59.4% anthracyclines 53% Taxanes 34% | VNR 60 mg/m² Day 1 + 8 q21 days CAP 500 mg/m² bid Day 1 – 14 | 36.7% | 8.0 TTP            | 32.0               | Neutropenia G3 12%         | [15] |
| Hassan et al. (2010) | 31           | Anthracyclines 100%  | VNR 60 mg/m² Day 1 + 8 q21 days CAP 1 gr/m² bid Day 1 – 14 | 67%   | 7.8                | 21                 | Neutropenia G3–4 16%       | [16] |
| Strada et al. (2012) | 46           | 97.8% anthracyclines 30.4% Taxanes 65.2% | VNR 60 mg/m² Day 1 + 8 q21 days CAP 1 gr/m² bid Day 1 – 14 | 76.0% | 8.4                | 34.3               | Neutropenia G3 13%        | [17] |
| Tawfik et al. (2013) | 28           | Anthracyclines 100%  Taxanes 60%       | VNR 60 mg/m² Day 1 + 8 q21 days CAP 1 gr/m² bid Day 1 – 14 | 57.1% | 8.6                | 27.2               | Neutropenia G3 24%         | [18] |
| Campone et al. (2013) | 44           | Anthracyclines 100%  Taxanes 18.2%     | VNR 60 mg/m² Day 1 + 8 q21 days CAP 1 gr/m² bid Day 1 – 14 | 31.8% | 7.2                | 22.2               | Neutropenia G3–4 47.7%     | [11] |
| Cazzaniga et al. (2016) | 35           | Not specified          | VNR 40 mg fixed dose three-times/week CAP 150077 day continuously | 35.5% | 7.9 TTP            | Not reported        | Neutropenia 1.6% of cycles Hand foot syndrome 1% of cycles | [14] |
| Cinieri et al. (2017) | 49           | Anthracyclines 80%    | VNR 60 mg/m² Day 1 + 8 q21 days CAP 1 gr/m² bid Day 1 – 14 | 67.3% | 7.6                | 30.2               | Neutropenia G3 25%; G4 25% | [15] |
| Present study        | 52           | 90% anthracyclines 21% Taxanes 71%     | VNR 60 mg/m² Day 1 + 8 q21 days CAP 1 gr/m² bid Day 1 – 14 | 58%   | 7.8                | 29.5               | Neutropenia G3 15%         | [12] |

Reported data refer only to evaluable patients. ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival; TTP: Time to progression.

Easily manageable. Severe grade 3–4 toxicities were only occasionally reported in a minority of cases. The good tolerability of the regimen is further strengthened by data reported by Rousseau et al., which tested the combination in a series of 80 patients older than 70 years with advanced cancer of the breast, lung and prostate [20]. In this series the functional status measured by activities of daily living was stabilized or improved in 82% of patients after three cycles of CT with excellent compliance in 69% of cases.
Oral vinorelbine & capecitabine as first-line therapy in MBC: a retrospective analysis

**Conclusion**

Despite recent therapeutic progress, systemic chemotherapy still maintains a pivotal role in the management of advanced TNBC. Scientific advances have recently provided a sound rationale for other treatment approaches for TNBC, such as the use of immunotherapy and poly(ADP-ribose) polymerase inhibitors. These two classes of drugs have shown promising results but have yet to demonstrate a proven OS benefit. Hopefully, other agents, such as antibody-drug conjugates and targeted therapies, will represent the next frontier in the treatment of this disease [21–24] (Figure 2).

**Future perspective**

In conclusion the above-reported data suggest that oral metronomic VNR plus CAP may be useful in the palliative treatment of patients with triple-negative and hormone-resistant MBC especially in order to reducing patients toxicity burden as may happen in elderly patients or in those with expect poor tolerance to taxanes with or without biologics. Another potential advantage of this metronomic approach may be represented by reduction of the affluence to the outpatient infusions clinic and or reducing difficulties to patients with geographical accessibility. Further studies are, however, needed to optimize and possibly improve efficacy of oral treatment for MBC.

**Summary points**

- The adoption of metronomic chemotherapy in the treatment of breast cancer is an important step forward in the management of this disease.
- The fluoropyrimidine capecitabine and the vinca alkaloid vinorelbine have been shown to be at least as active.
- Our data confirm the activity and safety of this all-oral regimen as first-line metronomic therapy being response rate.

**Author contributions**

Study concept and design: MR Valerio and V Gebbia. Acquisition, analysis and interpretation of data: V Gebbia and D Piazza. Drafting of the manuscript: V Gebbia. Critical revision of the manuscript: all authors. All authors read and approved the final manuscript.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research
The authors state that they have obtained appropriate Institutional Review Board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Open access
This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References
Papers of special note have been highlighted as: ● of interest

1. Banna GL, Collovè E, Gebbia V et al. Anticancer oral therapy: emerging related issues. Cancer Treat. Rev. 36, 595–605 (2010).
2. Cazzaniga ME, Dionisio MR, Riva F. Metronomic chemotherapy for advanced breast cancer patients. Cancer Lett. 400, 252–258 (2017).
3. Pajk B, Cufer T, Canney P et al. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized Phase II trial. Breast 17, 180–185 (2008).
4. Nolli F, Catania C, Sanna G et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann. Oncol. 17, 322–329 (2006).
5. Petrelli F, Di Cosimo S, Lonati V, Barni S. Vinorelbine with capcitabine, an evergreen doublet for advanced breast cancer: a systematic literature review and pooled-analysis of Phase II–III studies. Clin. Breast Cancer 16, 327–334 (2016).
6. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
7. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin. Oncol. 14, 65–74 (1987).
8. Caparica R, Lambertini M, de Azambuja E. How I treat metastatic triple-negative breast cancer. ESMO Open 4, e000504 (2019).
9. Gupta GK, Collier AL, Lee D et al. Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers 12(9), 2392 (2020).
10. Mo H, Xu B. Progress in systemic therapy for triple-negative breast cancer. Front. Med. doi:10.1007/s11845-020-0741-5 (2020).
11. Campone M, Dohrovolskaya N, Tjulandin S et al. A three-arm randomized Phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Breast 19, 240–249 (2013).
12. Finek J, Holubec I Jr, Svoboda T et al. A Phase II trial of oral vinorelbine and capcitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res. 29(2), 667–670 (2009).
13. Nolli F, Crivelli D, Martioli R et al. Phase II study of an all-oral combination of vinorelbine with capcitabine in patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 64, 673–680 (2009).
14. Tuhiana-Mathieu N, Bougnoux P, Becquart D et al. All-oral combination of oral vinorelbine and capcitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an international Phase II Trial. Br. J. Cancer 101, 232–237 (2009).
15. Gampenrieder SP, Barthsch R, Matzneller P et al. Capcitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced and metastatic breast cancer. Breast Care 5, 158–162 (2010).
16. Hassan M, Osman MM. Combination of oral vinorelbine and capcitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study. Hematol. Oncol. Stem Cell Ther. 3, 185–190 (2010).
17. Strada MR, Palumbo R, Bernardo A et al. Intravenous or oral vinorelbine plus capcitabine as first-line treatment in HER2– metastatic breast cancer: joint analysis of 2 consecutive prospective Phase II trials. Clin. Breast Cancer 12, 30–39 (2012).
18. Tawfik H, Rostom Y, Elghazaly H. All-oral combination of vinorelbine and capcitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. Cancer Chemother. Pharmacol. 71, 913–919 (2013).
19. Cinieri S, Chan A, Altundag K et al. Final results of the randomized Phase II NorCap-CA223 trial comparing first-line all-oral versus taxane-based chemotherapy for HER2-negative metastatic breast cancer. Clin. Breast Cancer 17, 91–99.e1 (2017).
● (Most recent study).
20. Rousseau F, Retornaz F, Joly F et al. Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: a multicentre pilot study of the French geriatric oncology group (GERICO). *Crit. Rev. Oncol. Hematol.* 76, 71–78 (2010).

21. Yang R, Shi YY, Han XH, Liu S. The impact of platinum-containing chemotherapies in advances triple-negative breast cancer: meta-analytical approach to evaluating its efficacy and safety. *Oncol. Res. Treat.* 11, 1–10 (2021).

22. Bartsch R. ESMO 2020: highlights in breast cancer. *Memo* doi:10.1007/s12254-021-00713-5 (2021).

23. Kumar S, Bal A, Das A et al. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer. *Breast Cancer Res. Treat.* doi:10.1007/s10549-021-06242-3 (2021).

24. O’Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. *World J. Clin. Oncol.* 12(3), 164–182 (2021).